Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics

PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiner, A, Bergmans, P, Cherubin, P, Keim, S, Llorca, P-M, Cosar, B, Petralia, A, Corrivetti, G, Hargarter, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512527/
https://www.ncbi.nlm.nih.gov/pubmed/25999398
http://dx.doi.org/10.1177/0269881115586284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512527/
https://www.ncbi.nlm.nih.gov/pubmed/25999398
http://dx.doi.org/10.1177/0269881115586284

Ejemplares similares